HLS vs. ACB, FIRE, EPI, OGI, WEED, CPH, ICC, RIV, LEAF, and RX
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Aurora Cannabis (ACB), Supreme Cannabis (FIRE), ESSA Pharma (EPI), Organigram (OGI), Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), and BioSyent (RX). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics vs. Its Competitors
HLS Therapeutics (TSE:HLS) and Aurora Cannabis (TSE:ACB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.
In the previous week, Aurora Cannabis had 12 more articles in the media than HLS Therapeutics. MarketBeat recorded 12 mentions for Aurora Cannabis and 0 mentions for HLS Therapeutics. HLS Therapeutics' average media sentiment score of 0.00 beat Aurora Cannabis' score of -0.07 indicating that HLS Therapeutics is being referred to more favorably in the media.
65.2% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 13.4% of Aurora Cannabis shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
HLS Therapeutics currently has a consensus price target of C$4.50, indicating a potential downside of 11.24%. Aurora Cannabis has a consensus price target of C$8.75, indicating a potential upside of 20.69%. Given Aurora Cannabis' stronger consensus rating and higher possible upside, analysts plainly believe Aurora Cannabis is more favorable than HLS Therapeutics.
HLS Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 2.71, suggesting that its stock price is 171% more volatile than the S&P 500.
Aurora Cannabis has a net margin of -22.55% compared to HLS Therapeutics' net margin of -38.70%. Aurora Cannabis' return on equity of -8.36% beat HLS Therapeutics' return on equity.
HLS Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aurora Cannabis beats HLS Therapeutics on 10 of the 16 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
This page (TSE:HLS) was last updated on 8/13/2025 by MarketBeat.com Staff
MarketBeat All Access